Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12543377 | 0.89 | EPHX2 (0.46) | EPHX2CYP2C9CYP2C19CYP2J2GABRA5 | |
| SCHEMBL12543378 | 0.89 | EPHX2 (0.46) | EPHX2CYP2C9CYP2C19CYP2J2GABRA5 | |
| SCHEMBL12693149 | 0.88 | PIK3CA (0.42) | GABRA5KCNH2 | |
| SCHEMBL12693160 | 0.85 | ELOVL6 (0.43) | KCNH2 | |
| SCHEMBL12693189 | 0.85 | PIK3CA (0.41) | KCNH2 | |
| SCHEMBL12693188 | 0.83 | EPHX2 (0.53) | EPHX2CYP2C9CYP2C19CYP2J2GABRA5 | |
| SCHEMBL12693087 | 0.81 | EPHX2 (0.44) | EPHX2CYP2C9CYP2C19CYP2J2GABRA5 | |
| SCHEMBL12541958 | 0.81 | CXCR3 (0.47) | EPHX2KCNH2 | |
| SCHEMBL12541960 | 0.81 | CXCR3 (0.47) | EPHX2KCNH2 | |
| SCHEMBL12543554 | 0.80 | KCNH2 (0.43) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | EPHX2 4370/4885CYP2C9 1022/4885CYP2C19 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.